SOUTH SAN FRANCISCO, Calif. (AP) _ Allogene Therapeutics Inc. (ALLO) on Wednesday reported a loss of $83.1 million in its third quarter.

On a per-share basis, the South San Francisco, California-based company said it had a loss of 58 cents.

The results beat Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research was for a loss of 62 cents per share.

The immuno-oncology company posted revenue of $49,000 in the period.

Allogene Therapeutics shares have declined 32% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $10.22, a decline of 48% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALLO at https://www.zacks.com/ap/ALLO

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News